Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight

Prior treatment

• A self-reported change in body weight greater than (\>) 5% within 90 days before screening irrespective of medical records.
• Consistent use of glucagon like peptide-1 (GLP-1) receptor agonists, including medication with glucagon like peptide-1 receptor agonist (GLP-1 RA) activity like dual GLP-1/gastric inhibitory peptide RAs, or amylin analogues before screening. Consistent use is defined as treatment.

Lab values

• HbA1c ≥ 6.5% (48 millimoles per mole \[mmol/mol\]) as measured by the central laboratory at screening.

• Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
• Female or male (sex at birth).
• Age 18 years or above at the time of signing the informed consent.
• Body mass index (BMI) of
  • ≥ 27.0 kilogram per square meter (kg/m\^2) with the presence of at least one weight-related comorbidity including, but not limited to, hypertension, dyslipidaemia, obstructive sleep apnoea or CV disease.
  • OR
  • ≥ 30.0 kg/m\^2.
• History of at least one self-reported unsuccessful dietary effort to lose body weight.